FREE War Room Open House!
Have you ever wondered how members had the chance to make 188 % Overnight Gain on FedEx? Or 121 % gains on Walmart in just over an hour? Now, you find out for yourself…

NASDAQ:MDGL - Madrigal Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $168.67
  • Forecasted Upside: 90.18 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
▼ -2.23 (-2.45%)

This chart shows the closing price for MDGL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Madrigal Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDGL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDGL

Analyst Price Target is $168.67
▲ +90.18% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Madrigal Pharmaceuticals in the last 3 months. The average price target is $168.67, with a high forecast of $204.00 and a low forecast of $114.00. The average price target represents a 90.18% upside from the last price of $88.69.

This chart shows the closing price for MDGL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
Live Trade Recommendations -- 100% FREE!
Live Trade Recommendations -- 100% FREE! No Cost… No Obligation… No B.S.! Join us June 26th - 30th for one week in The War Room. Get ALL our training, research… and real-time trade recommendations.

Current Consensus is Buy

The current consensus among 10 investment analysts is to buy stock in Madrigal Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/28/2021B. RileyReiterated RatingBuyLow
5/17/2021Canaccord GenuityBoost Price TargetBuy$179.00 ➝ $193.00Low
3/4/2021Chardan CapitalBoost Price TargetBuy$202.00 ➝ $203.00High
3/2/2021OppenheimerLower Price TargetOutperform$200.00 ➝ $190.00High
2/26/2021Chardan CapitalBoost Price TargetBuy$202.00 ➝ $203.00Medium
11/23/2020Evercore ISIReiterated RatingOutperform$180.00Low
11/12/2020Canaccord GenuityLower Price TargetBuy$198.00 ➝ $177.00Low
11/8/2020OppenheimerReiterated RatingBuyMedium
11/6/2020Chardan CapitalReiterated RatingBuy$205.00Medium
11/6/2020The Goldman Sachs GroupBoost Price TargetNeutral$118.00 ➝ $126.00Low
11/6/2020BMO Capital MarketsBoost Price TargetMarket Perform$119.00 ➝ $124.00Medium
11/6/2020HC WainwrightBoost Price TargetBuy$165.00 ➝ $184.00Medium
11/5/2020Piper SandlerLower Price TargetOverweight$208.00 ➝ $204.00High
8/27/2020Canaccord GenuityReiterated RatingBuyLow
8/12/2020Canaccord GenuityReiterated RatingBuy$198.00High
8/6/2020OppenheimerReiterated RatingBuy$200.00Medium
8/6/2020Stifel NicolausReiterated RatingHold$114.00High
7/30/2020Piper SandlerInitiated CoverageOverweight$208.00High
6/24/2020OppenheimerReiterated RatingBuy$200.00High
6/4/2020BMO Capital MarketsInitiated CoverageMarket Perform$135.00Medium
5/22/2020B. RileyBoost Price TargetBuy$134.00 ➝ $174.00High
5/8/2020HC WainwrightLower Price TargetBuy$215.00 ➝ $168.00Medium
5/7/2020Stifel NicolausReiterated RatingHold$116.00Medium
5/5/2020Chardan CapitalInitiated CoverageBuy$205.00High
4/15/2020B. RileyReiterated RatingBuy$134.00Low
4/14/2020Stifel NicolausReiterated RatingHoldLow
3/5/2020CitigroupLower Price Target$166.00 ➝ $155.00Low
2/27/2020CowenReiterated RatingBuyHigh
1/30/2020Canaccord GenuityInitiated CoverageBuy$198.00High
1/9/2020UBS GroupUpgradeNeutral ➝ Buy$125.00 ➝ $127.00High
1/2/2020SVB LeerinkReiterated RatingOutperformLow
12/2/2019CitigroupLower Price TargetBuy$173.00 ➝ $166.00High
11/12/2019CowenReiterated RatingBuyMedium
11/7/2019HC WainwrightLower Price TargetBuy$225.00 ➝ $215.00High
11/6/2019CowenReiterated RatingBuyHigh
9/17/2019CitigroupLower Price TargetBuy$186.00 ➝ $173.00Low
8/9/2019B. RileySet Price TargetBuy$134.00High
8/8/2019CowenReiterated RatingBuyLow
8/7/2019Stifel NicolausSet Price TargetHold$126.00Low
7/3/2019HC WainwrightReiterated RatingBuy$225.00Low
6/24/2019Stifel NicolausInitiated CoverageHold ➝ Hold$126.00Medium
6/10/2019B. RileyUpgradeNeutral ➝ Buy$126.00 ➝ $128.00Low
5/15/2019CitigroupLower Price TargetBuy$200.00 ➝ $186.00Medium
5/9/2019HC WainwrightReiterated RatingBuyLow
4/17/2019CowenReiterated RatingBuyHigh
3/28/2019UBS GroupBoost Price TargetNeutral ➝ Positive$143.00Medium
2/28/2019HC WainwrightReiterated RatingBuy ➝ Buy$313.00 ➝ $228.00Medium
2/22/2019SVB LeerinkInitiated CoverageOutperformLow
1/23/2019UBS GroupInitiated CoverageNeutral ➝ Neutral$119.00High
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformMedium
12/12/2018HC WainwrightReiterated RatingBuy$313.00Low
12/12/2018CitigroupLower Price TargetBuy$200.00Low
12/11/2018B. RileyInitiated CoverageNeutral ➝ Neutral$124.00 ➝ $124.00Low
12/4/2018OppenheimerSet Price TargetBuy$200.00High
11/19/2018OppenheimerLower Price TargetOutperform$300.00 ➝ $200.00High
11/19/2018Raymond JamesDowngradeMarket Perform ➝ UnderperformHigh
11/16/2018Evercore ISIUpgradeIn-Line ➝ Outperform$222.00 ➝ $250.00High
11/13/2018OppenheimerSet Price TargetBuy$300.00High
11/7/2018CowenReiterated RatingBuyHigh
9/18/2018OppenheimerSet Price TargetBuy$300.00High
9/4/2018CitigroupInitiated CoverageBuy ➝ Buy$340.00High
8/8/2018OppenheimerSet Price TargetBuy$300.00Low
8/6/2018The Goldman Sachs GroupDowngradeBuy ➝ Neutral$314.00Medium
6/28/2018Raymond JamesInitiated CoverageMarket PerformMedium
6/27/2018Evercore ISIReiterated RatingIn-LineLow
6/7/2018Evercore ISILower Price TargetOutperform$300.00 ➝ $281.00Low
6/1/2018Roth CapitalBoost Price TargetBuy$210.00 ➝ $400.00Medium
6/1/2018HC WainwrightBoost Price TargetBuy ➝ Buy$178.00 ➝ $313.00Medium
5/31/2018CowenReiterated RatingBuyHigh
5/31/2018Evercore ISIBoost Price TargetOutperform$300.00Medium
5/31/2018OppenheimerUpgradeMarket Perform ➝ Outperform$300.00High
5/31/2018UBS GroupUpgradeMarket Perform ➝ OutperformHigh
5/31/2018The Goldman Sachs GroupReiterated RatingBuy$191.00 ➝ $314.00High
5/31/2018JMP SecuritiesReiterated RatingOutperform$150.00 ➝ $300.00High
5/24/2018HC WainwrightBoost Price TargetBuy$178.00Medium
5/10/2018CowenReiterated RatingBuyHigh
5/8/2018OppenheimerSet Price TargetHold$130.00Medium
4/16/2018OppenheimerInitiated CoverageHold$130.00Medium
4/13/2018CowenReiterated RatingBuyHigh
3/23/2018The Goldman Sachs GroupInitiated CoverageBuy$191.00High
2/28/2018CowenInitiated CoverageOutperformHigh
2/9/2018Roth CapitalBoost Price TargetBuy$170.00 ➝ $210.00Low
2/8/2018Evercore ISIReiterated RatingOutperform ➝ Outperform$140.00 ➝ $175.00High
1/30/2018HC WainwrightBoost Price TargetBuy ➝ Buy$105.00 ➝ $156.00High
12/11/2017Roth CapitalBoost Price TargetBuy$82.00 ➝ $170.00Low
12/7/2017Evercore ISIBoost Price TargetOutperform$65.00 ➝ $140.00Low
12/6/2017JMP SecuritiesBoost Price TargetOutperform$63.00 ➝ $125.00High
12/6/2017HC WainwrightBoost Price TargetBuy ➝ Buy$54.00 ➝ $105.00High
11/30/2017Roth CapitalSet Price TargetBuy$62.00 ➝ $82.00High
11/29/2017HC WainwrightInitiated CoverageBuy ➝ Buy$54.00Medium
10/19/2017Roth CapitalInitiated CoverageBuy ➝ Buy$62.00N/A
10/13/2017JMP SecuritiesBoost Price TargetOutperform$40.00 ➝ $63.00N/A
9/22/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$65.00High
1/3/2017JMP SecuritiesInitiated CoverageOutperform$40.00N/A
(Data available from 7/25/2016 forward)
Madrigal Pharmaceuticals logo
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor-Ã agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $88.69
Low: $88.28
High: $91.05

50 Day Range

MA: $105.74
Low: $88.69
High: $134.00

52 Week Range

Now: $88.69
Low: $88.28
High: $142.62


121,438 shs

Average Volume

154,076 shs

Market Capitalization

$1.47 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Madrigal Pharmaceuticals?

The following Wall Street research analysts have issued reports on Madrigal Pharmaceuticals in the last year: B. Riley, BMO Capital Markets, Canaccord Genuity, Chardan Capital, Evercore ISI, HC Wainwright, Oppenheimer Holdings Inc., Piper Sandler, Stifel Nicolaus, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for MDGL.

What is the current price target for Madrigal Pharmaceuticals?

9 Wall Street analysts have set twelve-month price targets for Madrigal Pharmaceuticals in the last year. Their average twelve-month price target is $168.67, suggesting a possible upside of 90.2%. Piper Sandler has the highest price target set, predicting MDGL will reach $204.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $114.00 for Madrigal Pharmaceuticals in the next year.
View the latest price targets for MDGL.

What is the current consensus analyst rating for Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals currently has 3 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDGL will outperform the market and that investors should add to their positions of Madrigal Pharmaceuticals.
View the latest ratings for MDGL.

What other companies compete with Madrigal Pharmaceuticals?

How do I contact Madrigal Pharmaceuticals' investor relations team?

Madrigal Pharmaceuticals' physical mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company's listed phone number is (484) 380-9263 and its investor relations email address is [email protected] The official website for Madrigal Pharmaceuticals is

Live Trade Recommendations -- 100% FREE!
Live Trade Recommendations -- 100% FREE! No Cost… No Obligation… No B.S.! Join us June 26th - 30th for one week in The War Room. Get ALL our training, research… and real-time trade recommendations.